Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 1 58 / https://doi.org/10.3332/ecancer.2007.58

Research

Resection of colorectal liver metastases following neoadjuvant chemotherapy

Background/aims: Hepatic resection in metastatic disease from colorectal cancer offers the best chance in selected cases for long-term survival. Neoadjuvant chemotherapy (NACT) has been advocated in some cases initially deemed irresectable, with few reports of the efficacy of such a strategy and the influence of the response to chemotherapy on the outcome of radical hepatic resection.

Methodology: Between December 1995 and May 2005, 27 patients with colorectal liver metastases (seven males, 20 females, mean age: 58 ± 8 years; range: 40–75) were treated with neoadjuvant chemotherapy. A seven-year survival analysis was performed. Chemotherapy included mainly 5-fluorouracil, leucovorin and either oxaliplatin or irinotecan for a median of eight courses.

Results: A total of 16 patients (59%) had synchronous and 11 (41%) metachronous metastases. During pre-operative chemotherapy, tumour regression occurred in ten cases (37%), stable disease in a further ten patients (37%) and progressive disease developed in seven cases (26%). The five-year overall survival for NACT responders was 64% and only 15% for non-responders (p=0.044).

Conclusions: The response to chemotherapy is likely to be a significant prognostic factor affecting survival after liver resection for cure.

Keywords: Response to neo-adjuvant chemotherapy for colorectal cancer liver metastases A key for improving survival Hepatic resection in metastatic disease from colorectal cancer offers the best chance in selected cases for long-term survival Neoadjuvant chemothera

Categories:

Lung & pleura

Loading Article Metrics ... Please wait

Related articles

Conference Report: Highlights of the 16th St Gallen International Breast Cancer Conference, Vienna, Austria, 20–23 March 2019: personalised treatments for patients with early breast cancer

Abstract | Full Article | PDF Published: 24 Apr 2019 / https://doi.org/10.3332/ecancer.2019.924

Research: Breast lesions with atypia in percutaneous biopsies, managed with surgery in the last 10 years

Abstract | Full Article | PDF | Spanish Published: 11 Apr 2019 / https://doi.org/10.3332/ecancer.2019.923

Case Report: Primary cardiac angiosarcoma diagnosed in the first trimester of pregnancy

Abstract | Full Article | PDF Published: 09 Apr 2019 / https://doi.org/10.3332/ecancer.2019.922

Clinical Study: Assessing the tolerability and efficacy of first-line chemotherapy in elderly patients with metastatic HER2−ve breast cancer

Abstract | Full Article | PDF Published: 03 Apr 2019 / https://doi.org/10.3332/ecancer.2019.921

Policy: Precision oncology in Latin America: current situation, challenges and perspectives

Abstract | Full Article | PDF | Spanish Published: 03 Apr 2019 / https://doi.org/10.3332/ecancer.2019.920



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation